NAS:NEOS (USA) Also trade in: Germany

Neos Therapeutics Inc

$ 1.67 -0.09 (-5.11%)
Volume: 275,690 Avg Vol (1m): 393,871
Market Cap $: 83.05 Mil Enterprise Value $: 94.97 Mil
P/E (TTM): 0.00 P/B: 72.65
Earnings Power Value -2.3
Net Current Asset Value -0.48
Tangible Book -0.26
Projected FCF 0
Median P/S Value 13.7
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 3/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt 0.77
Cash-To-Debt ranked lower than
69.38% of 859 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 91151, Med: 2.03, Min: -0.01
NEOS: 0.77
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.28, Med: 0.88, Max: 3
Current: 0.77
0.28
3
Equity-to-Asset 0.01
Equity-to-Asset ranked lower than
97.72% of 788 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1.78, Med: 0.64, Min: -27.83
NEOS: 0.01
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -1.74, Med: 0.08, Max: 0.66
Current: 0.01
-1.74
0.66
Debt-to-Equity 45.99
Debt-to-Equity ranked lower than
100.00% of 596 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 31.22, Med: 0.32, Min: 0.01
NEOS: 45.99
Ranked among companies with meaningful Debt-to-Equity only.
Debt-to-Equity range over the past 10 years
Min: -41.03, Med: 0.44, Max: 45.99
Current: 45.99
-41.03
45.99
Debt-to-EBITDA -1.61
Debt-to-EBITDA ranked lower than
100.00% of 495 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 343059.67, Med: 1.92, Min: 0.01
NEOS: -1.61
Ranked among companies with meaningful Debt-to-EBITDA only.
Debt-to-EBITDA range over the past 10 years
Min: -1.61, Med: -1.37, Max: -0.88
Current: -1.61
-1.61
-0.88
Piotroski F-Score 4
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -4.29
DISTRESS
GREY
SAFE
Beneish M-Score -2.46
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC -247.55%
WACC 16.3%

Profitability & Growth : 5/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -68.28
Operating Margin ranked lower than
87.39% of 801 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 8950, Med: 7.97, Min: -232970.37
NEOS: -68.28
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -2436.94, Med: -728.33, Max: -68.28
Current: -68.28
-2436.94
-68.28
Net Margin % -83.20
Net Margin ranked lower than
87.53% of 802 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 304900, Med: 5.32, Min: -216285.19
NEOS: -83.2
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -2750.53, Med: -818.27, Max: -83.2
Current: -83.2
-2750.53
-83.2
ROA % -47.90
ROA ranked lower than
88.17% of 871 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 943.36, Med: 2.88, Min: -1851.14
NEOS: -47.9
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -81.67, Med: -47.92, Max: -36.7
Current: -47.9
-81.67
-36.7
ROC (Joel Greenblatt) % -450.36
ROC (Joel Greenblatt) ranked lower than
89.24% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 34233.33, Med: 11.23, Min: -2671900
NEOS: -450.36
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1242.85, Med: -511.96, Max: -234.2
Current: -450.36
-1242.85
-234.2
3-Year Total Revenue Growth Rate 136.20
3-Year Revenue Growth Rate ranked higher than
99.56% of 689 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 291.9, Med: 5.8, Min: -100
NEOS: 45.7
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 45.7, Med: 105.5, Max: 176.2
Current: 45.7
45.7
176.2
3-Year Total EBITDA Growth Rate -18.10
3-Year EBITDA Growth Rate ranked lower than
88.92% of 704 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 299.6, Med: 7.3, Min: -343.2
NEOS: 27.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: -66, Med: -25.4, Max: 27.2
Current: 27.2
-66
27.2
3-Year EPS w/o NRI Growth Rate 28.50
3-Year EPS w/o NRI Growth Rate ranked lower than
82.35% of 663 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 385.8, Med: 8.9, Min: -403.2
NEOS: 28.5
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -16.8, Max: 28.5
Current: 28.5
0
28.5

» NEOS's 30-Y Financials

Financials (Next Earnings Date: 2019-08-08)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:NEOS

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare XCNQ:ISOL XKRX:011040 TSXV:THCX NAS:TOCA NAS:CPRX XCNQ:LHS NZSE:CVT NAS:EOLS OCSE:VELO DHA:ACI XKRX:002250 XKLS:7081 TSE:4594 IST:DEVA TSE:4538 XKRX:023910 BOM:506235 NAS:ACET TSE:4597 XTER:93M
Traded in other countries NTE.Germany
Address 2940 North Highway 360, Grand Prairie, TX, USA, 75050
Neos Therapeutics Inc is a pharmaceutical company, engaged in the development, manufacture, and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technologies. The product portfolio of the company includes Methylphenidate XR-ODT and Amphetamine XR oral suspension commonly prescribed medicine for the treatment of ADHD. In addition, it also manufactures and markets generic Tussionex, a hydrocodone polistirex and chlorpheniramine polistirex XR liquid suspension product indicated for the relief of cough. Geographically, it operates through United States and derives revenue through sale of products.

Ratios

Current vs industry vs history
PB Ratio 72.65
PB Ratio ranked lower than
100.00% of 819 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 227.39, Med: 2.64, Min: 0.05
NEOS: 72.65
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.78, Med: 7.22, Max: 142.61
Current: 72.65
1.78
142.61
PS Ratio 1.13
PS Ratio ranked lower than
69.94% of 775 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 9105.26, Med: 3.1, Min: 0.03
NEOS: 1.13
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 1.04, Med: 9.27, Max: 126.13
Current: 1.13
1.04
126.13
EV-to-EBIT -2.69
EV-to-EBIT ranked lower than
100.00% of 572 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 1015380.11, Med: 17.85, Min: 0.13
NEOS: -2.69
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -9.6, Med: -3.55, Max: -1.3
Current: -2.69
-9.6
-1.3
EV-to-EBITDA -2.91
EV-to-EBITDA ranked lower than
100.00% of 597 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 341528.02, Med: 15.24, Min: 0.12
NEOS: -2.91
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -11.1, Med: -3.9, Max: -1.3
Current: -2.91
-11.1
-1.3
EV-to-Revenue 1.74
EV-to-Revenue ranked lower than
68.93% of 795 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 23858.8, Med: 3.24, Min: 0.03
NEOS: 1.74
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 1.5, Med: 11.3, Max: 86.6
Current: 1.74
1.5
86.6
Current Ratio 1.49
Current Ratio ranked lower than
62.81% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 2.39, Min: 0.02
NEOS: 1.49
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 0.94, Med: 3.04, Max: 8.04
Current: 1.49
0.94
8.04
Quick Ratio 1.27
Quick Ratio ranked lower than
58.95% of 855 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 413.44, Med: 1.87, Min: 0.02
NEOS: 1.27
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 0.71, Med: 2.84, Max: 7.84
Current: 1.27
0.71
7.84
Days Inventory 155.15
Days Inventory ranked lower than
85.96% of 755 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 950.68, Med: 119.8, Min: 0.2
NEOS: 155.15
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 60.35, Med: 135.97, Max: 227.62
Current: 155.15
60.35
227.62
Days Sales Outstanding 157.28
Days Sales Outstanding ranked lower than
91.04% of 770 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 864.61, Med: 81.76, Min: 0.1
NEOS: 157.28
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 157.28, Med: 193.46, Max: 375.68
Current: 157.28
157.28
375.68
Days Payable 111.07
Days Payable ranked higher than
71.37% of 758 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 952.38, Med: 76.32, Min: 0.04
NEOS: 111.07
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 111.07, Med: 207.56, Max: 298.14
Current: 111.07
111.07
298.14

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -26.30
3-Year Share Buyback Rate ranked lower than
80.74% of 571 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 100, Med: -5.3, Min: -815
NEOS: -26.3
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -26.3, Med: -26, Max: -3.5
Current: -26.3
-26.3
-3.5

Valuation & Return

Current vs industry vs history
Price-to-Median-PS-Value 0.12
Price-to-Median-PS-Value ranked higher than
82.23% of 743 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 238.36, Med: 0.94, Min: 0.01
NEOS: 0.12
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.11, Med: 1.01, Max: 12.22
Current: 0.12
0.11
12.22
Earnings Yield (Joel Greenblatt) % -37.91
Earnings Yield (Greenblatt) ranked lower than
92.50% of 867 companies
in the Drug Manufacturers - Specialty & Generic industry.
Industry Max: 769.23, Med: 3.31, Min: -333.33
NEOS: -37.91
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -78.6, Med: -28.05, Max: -10.4
Current: -37.91
-78.6
-10.4

More Statistics

Revenue (TTM) (Mil) $ 53.89
EPS (TTM) $ -1.33
Beta 2.34
Volatility % 67.58
52-Week Range $ 1.4 - 7.75
Shares Outstanding (Mil) 49.72

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 4
Positive ROA N
Positive CFROA N
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y